Cutaneous melanoma, a fatal and aggressive tumor, has witnessed a transformative shift in its clinical management over the past decade with the advent of anti-programmed cell death 1 (PD1) and anti-cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) immunotherapies, as well as targeted therapies. The gene discussed is PDCD1; the disease is neoplasm.